Apolipoprotein C3 as A Paradoxical Inhibitor of Platelet Aggregation and Thrombosis – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Waltraud C. Schrottmaier et al, adding:
”Elevated Levels of Apolipoprotein C3 Impair Platelet Function and Reduce Thrombosis
ApoC3, a known cardiovascular risk factor, paradoxically acts as a lipoprotein-derived inhibitor of platelet aggregation and thrombosis by modulating AKT and VASP signaling and disrupting actin cytoskeleton remodeling, potentially counterbalancing its proatherogenic effects in hyperlipidemia.”
Title: Elevated levels of apolipoprotein C3 impair platelet function and reduce thrombosis
Authors: Waltraud C. Schrottmaier, Julia B. Kral-Pointner, Marion Mussbacher, Manuel Salzmann, Bernhard Hochreiter, Anita Pirabe, Theresa Reiter, Sigrun Badrnya, Johannes A. Schmid, Ivo Volf, Alice Assinger
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 11:47Rucha Patil: Strengthening Evidence-Based Haemophilia Care Across India
-
Aug 11, 2026, 11:38Maria Hadjidemetriou: The Patient Perspective in Thalassemia Care
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy